appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Astrazeneca Pharma India Ltd
ASTRAZEN
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
AstraZeneca Pharma India Limited is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines for core areas of healthcare.
Brands
Brands
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
AstraZeneca Pharma India plans to sell its Bengaluru production facility
3 weeks ago•Business Today
AstraZeneca Pharma India Plans To Sell Bengaluru Manufacturing Plant, Check Details - News18
3 weeks ago•News18
AstraZeneca Pharma fall 3% despite healthy Q2 net profit, revenue growth
1 month ago•Moneycontrol
Recent EventsAll events
Appointment
AstraZeneca Pharma India Limited has informed the Exchange regarding Appointment of Ms Hooi Bien Chuah as Non- Executive Director of the company w.e.f. November 09, 2023. | Download
AstraZeneca Pharma India Limited has informed the Exchange regarding Appointment of Ms Hooi Bien Chuah as Non- Executive Director of the company w.e.f. November 09, 2023. | Download
Cash Dividend
Final • Div/Share: ₹ 16
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant